Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment

ID#: NCT05825898

Age: 18 years - 66+

Gender: All

Recruitment Status: Enrolling by invitation

Start Date: September 01, 2022

End Date: June 01, 2023

Summary: Tricuspid regurgitation (TR) is a public health problem: moderate / severe TR are common, especially in ageing populations, and affect 4% of the population >75 years old, totaling approximately 1.6 million in the US and 3 million in Europe. TR is associated with an increased risk of mortality and morbidity. Contrasting with TR prevalence and the magnitude of the problem, the vast majority of patients are medically treated with diuretics to relieve their symptoms and a curative surgical treatment for isolated severe TR is seldom performed. Reluctance to perform an ITVS can be explained in the one hand by the limited evidence that TR correction improves outcomes and on the other hand, ITVS is associated to high observed in-hospital mortality rates (≈ 10% remarkably consistent in most series across the literature). Severity of the clinical presentation is the main predictor of outcome after surgery. The TRI-SCORE, is a dedicated, simple and accurate risk score model to predict in-hospital mortality after ITVS that could guide the clinical decision-making process at the individual level. Excellent outcomes can be achieved when patients present with low TRI-SCORE. These results suggest adopting a more pro-active approach for TV interventions, and to intervene earlier in the course of the disease in patients with severe isolated TR, irrespective of TR mechanism / etiology, before the occurrence of advanced / irreversible consequences such as severe RV dilatation / dysfunction, renal and liver failure, and intractable heart failure. Recently transcatheter tricuspid valve interventions (TTVI) have emerged recently as a less invasive option to surgery to cure patients with TR. What is the best treatment between medical, surgical or transcatheter therapy to consider and the best timing for each patient are not clearly defined. The aim of the study is to compare outcome of patients with significant functional TR according to medical, transcatheter or surgical treatment after matching per TRISCORE.
Eligibility:

Inclusion Criteria:

- Age ≥ 18 years

- Isolated (no left-valvular heart disease (mitral regurgitation) >2)

- AND Functional

- AND Moderate to severe or severe Tricuspid regurgitation

Exclusion Criteria:

- Congenital valvular disease,

- Previous tricuspid valve intervention,

- Organic tricuspid valvular disease

- Associated valvular heart disease
Find a Clinical Trial